[go: up one dir, main page]

AR008444A1 - Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii - Google Patents

Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii

Info

Publication number
AR008444A1
AR008444A1 ARP970104293A ARP970104293A AR008444A1 AR 008444 A1 AR008444 A1 AR 008444A1 AR P970104293 A ARP970104293 A AR P970104293A AR P970104293 A ARP970104293 A AR P970104293A AR 008444 A1 AR008444 A1 AR 008444A1
Authority
AR
Argentina
Prior art keywords
diabetes
antagonists
type
leptine
employment
Prior art date
Application number
ARP970104293A
Other languages
English (en)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of AR008444A1 publication Critical patent/AR008444A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere al empleo de antagonistas de leptina para la preparacion de un medicamento en la diabetes de tipo II, en particular a un fragmento de leptinamurínica de los animoácidos 116 a 167 o 116 a 166 como antagonista de leptina, a un fragmentod e leptina murínica que contiene los aminoácidos 116 a 167 o 116a 166, así como a un medicamento correspondiente.
ARP970104293A 1996-09-20 1997-09-18 Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii AR008444A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19638487 1996-09-20

Publications (1)

Publication Number Publication Date
AR008444A1 true AR008444A1 (es) 2000-01-19

Family

ID=7806282

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104293A AR008444A1 (es) 1996-09-20 1997-09-18 Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii

Country Status (18)

Country Link
US (1) US6399745B1 (es)
EP (1) EP0956302A1 (es)
JP (1) JP2001500869A (es)
KR (1) KR20010029537A (es)
CN (1) CN1230966A (es)
AR (1) AR008444A1 (es)
AU (1) AU735178B2 (es)
BR (1) BR9711513A (es)
CA (1) CA2266585A1 (es)
CZ (1) CZ90999A3 (es)
HU (1) HUP9904023A3 (es)
ID (1) ID21861A (es)
IL (1) IL129057A0 (es)
NO (1) NO991186L (es)
PL (1) PL332458A1 (es)
RU (1) RU2201249C2 (es)
WO (1) WO1998012224A1 (es)
ZA (1) ZA978455B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1101112B1 (en) 1998-07-28 2004-10-06 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Leptin-mediated gene-induction
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1214351A2 (en) 1999-09-22 2002-06-19 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
AU2001281784B2 (en) 2000-05-22 2005-09-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
RU2378285C2 (ru) 2004-02-11 2010-01-10 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
US7407929B2 (en) * 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
BRPI0518241A (pt) 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP2009530407A (ja) * 2006-03-23 2009-08-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2219664A1 (en) * 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8778890B2 (en) 2009-03-31 2014-07-15 Temple University—Of the Commonwealth System of Higher Education Leptin antagonist and methods of use
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
DK2621519T3 (en) 2010-09-28 2017-10-16 Aegerion Pharmaceuticals Inc Leptin-ABD fusion polypeptides with improved duration of action
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
HRP20181879T1 (hr) 2012-09-27 2019-02-08 The Children's Medical Center Corporation Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
LT3074033T (lt) 2013-11-26 2019-02-25 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh) 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
EP3509624B1 (en) 2016-09-12 2023-08-09 Amryt Pharmaceuticals Inc. Methods of detecting anti-leptin neutralizing antibodies
WO2019043382A1 (en) * 2017-08-31 2019-03-07 University Of Dundee DERIVED LEPTIN PEPTIDES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CN119823265B (zh) * 2025-01-02 2026-01-06 江苏省农业科学院 抗leptin的单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2040926C1 (ru) * 1991-11-25 1995-08-09 Анатолий Григорьевич Гриценко Способ лечения сахарного диабета
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
WO1997002004A2 (en) * 1995-06-30 1997-01-23 Eli Lilly And Company Methods for treating diabetes
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US5922678A (en) * 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
WO1998012224A1 (en) 1998-03-26
IL129057A0 (en) 2000-02-17
NO991186D0 (no) 1999-03-11
PL332458A1 (en) 1999-09-13
ID21861A (id) 1999-08-05
AU4458697A (en) 1998-04-14
CN1230966A (zh) 1999-10-06
AU735178B2 (en) 2001-07-05
JP2001500869A (ja) 2001-01-23
CA2266585A1 (en) 1998-03-26
RU2201249C2 (ru) 2003-03-27
KR20010029537A (ko) 2001-04-06
CZ90999A3 (cs) 1999-06-16
BR9711513A (pt) 1999-08-24
NO991186L (no) 1999-03-11
EP0956302A1 (en) 1999-11-17
ZA978455B (en) 1998-03-20
US6399745B1 (en) 2002-06-04
HUP9904023A2 (hu) 2000-03-28
HUP9904023A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
CL2004000897A1 (es) Uso de una toxina botulinica seleccionada del grupo que contiene los tipos a,b,c,d,e,f y g para preparar un medicamento util para controlar la cefalea sinusal a un paciente.
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
IT8809543A0 (it) Pistone per siringhe che rende automaticamente inoffensivo l'ago ipodermico, all'uopo modificato, dopo l'uso
DE69017356D1 (de) Ampulle für nadelloses, hypodermisches Injektionsgerät.
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2196361T3 (es) Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
ES2170813T3 (es) Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina.
CY1108401T1 (el) Παραγωγα πυρρολοϊμιδαζολης, η παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιεχουν και η χρηση τους ως νοοτροπικων παραγοντων
ES2125567T3 (es) Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.
AR033957A1 (es) Nuevos compuestos
TR199902980T2 (xx) Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
DOP2006000231A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
NO985571L (no) Legemiddel for autoimmunsykdommer
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
AR028987A1 (es) Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad

Legal Events

Date Code Title Description
FB Suspension of granting procedure